Santen Ventures

The firm primarily sources through the parent company's global network of ophthalmology key opinion leaders, academic institutions, and industry conferences like the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Its proximity to the UC Berkeley and UCSF ecosystems provides additional Bay Area deal flow. Santen's internal R&D and clinical teams participate in technical diligence, giving the venture group a distinct filter for assets with genuine translational potential in eye care.

Santen Ventures functions with a hybrid structure typical of strategic corporate venture arms. While it maintains its own investment team and sourcing autonomy, material commitments require alignment with the parent's corporate development and R&D leadership. This ensures portfolio companies fit Santen's long-term therapeutic pipeline rather than optimizing purely for financial return — a posture that can advantage founders seeking a hands-on corporate partner but may limit the speed of pure-play financial decision-making.

The firm concentrates on seed and start-up stages, typically entering at Series A or earlier. Check sizes range approximately from $2 million to $10 million, with the option to follow on in subsequent rounds when the technology aligns with a Santen therapeutic area of interest. It does not typically participate in late-stage crossover rounds or purely pre-IPO financings.

Santen's publicly stated corporate focus excludes non-ophthalmic indications. The venture unit is unlikely to invest in pure-play aesthetics, dermatology, or general wellness unless the technology demonstrates a clear application to ocular surface disease, glaucoma drainage, or retinal delivery. Additionally, the firm has not historically pursued service-model businesses like optometry chain roll-ups, preferring asset-level therapeutics and devices.

The venture arm operates as an external innovation scout, enabling Santen to access early-stage science without building all capabilities internally. Portfolio companies often enter co-development partnerships or licensing discussions with Santen's R&D organization as the assets mature, though investment does not guarantee acquisition. This creates a proprietary pipeline advantage while maintaining some financial discipline — a model that has produced exits through both trade sales to Santen and open-market transactions to companies like Novartis (per public record, 2019).

It is structurally a single-category investor. Unlike a generalist fund that allocates across oncology, cardiovascular, and ophthalmology, Santen Ventures only looks at eye-related assets. This focus means the diligence team, advisory network, and commercial path are all optimized for one therapeutic area. The trade-off is portfolio concentration: the firm cannot hedge sector risk by diversifying into unrelated biotech verticals, which makes individual deal selection especially weighty.

The firm operates a direct-investment model, taking equity positions in portfolio companies rather than allocating capital as a limited partner into independent VC funds. This ensures strategic alignment — Santen Ventures wants board observation rights, technical collaboration, and visibility into the asset's progress, which third-party fund commitments generally do not provide.